Skip to main content

Table 1 General characteristics of included systematic reviews

From: Efficacy of systemic oncological treatments in patients with advanced esophageal or gastric cancers at high risk of dying in the middle and short term: an overview of systematic reviews

Author, year Country Time frame Search strategy/ Database RCTs (n) RCTs (n) included in our overview. P I C O Funding Conflicts of interest. AMSTAR assessment
Iacovelli 2014 [23] USA From January 2004 to February 2014 Cochrane Central Register of Controlled Trials, MEDLINE, PubMed. 5 5 Gastric cancer CT, Biological, or targeted therapy BSC / Supportive care Functional status, OS No None CRITICALLY LOW
TerVeer 2016 [24] Netherlands Up to January 2016 Cochrane Central Register of Controlled Trials, EMBASE, MEDLINE. 28 8 Esophageal, gastric, and GEJ cancer CT, Biological, or targeted therapy BSC / Placebo OS, PFS, Toxicity No Yes CRITICALLY LOW
Wang 2016 [25] China Up to December 31, 2015 Cochrane Library, EMBASE, PubMed 10 3 Gastric cancer Biological or targeted therapy Placebo OS Public None LOW
Chan a 2017 [26] Australia Up to December 2014 Cochrane Central Register of Controlled Trials, EMBASE, PubMed. 15 4 Gastric and GEJ cancer Biological or targeted therapy Placebo OS, PFS, Toxicity, QoL No Yes CRITICALLY LOW
Chan b 2017 [27] China Up to 2016 CINAHL, Cochrane Central Register of Controlled Trials, EMBASE, MEDLINE 5 5 Gastric and GEJ cancer CT, Biological, or targeted therapy BSC / Placebo OS, PFS, Toxicity No None HIGH
Harvey 2017 [28] UK Between 1990 and 2015 PubMed, Scopus. 5 5 Gastric and GEJ cancer CT BSC OS NR NR CRITICALLY LOW
Janmaat 2017 [15] Netherlands Up to 13 May 2015 Cochrane Central Register of Controlled Trials, Clinicaltrials.gov, EMBASE, Google Scholar, MEDLINE, PubMed, Web of Science, WHO International Clinical Trials Registry Platform (ICTRP) 41 5 Esophageal and GEJ cancer CT, Biological, or targeted therapy BSC / Placebo / Non-specified OS Public None HIGH
Wagner 2017 [29] Switzerland Up to June 2016 Cochrane Central Register of Controlled Trials, MEDLINE, Hand searched reference lists from studies, abstracts, conference. 64 3 Gastric and GEJ cancer CT BSC OS Public Yes HIGH
Wang 2017 [30] China Up to December 2015 Embase, Medline, the Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, EMBASE, MEDLINE 9 2 Gastric cancer Biological or targeted therapy Placebo Toxicity NR None MODERATE
Xie 2017 [31] China Between January 1st, 2000 and October 1st, 2016 Cochrane Library and Scopus, EMBASE, 23 2 Gastric and GEJ cancer CT, Biological, or targeted therapy Placebo OS NR None CRITICALLY LOW
Zhu 2017 [32] Canada Up to June 2014 American Society of Clinical Oncology abstracts, Cochrane Central Register of Controlled Trials, EMBASE, MEDLINE. 8 5 Gastric and GEJ cancer CT, Biological, or targeted therapy BSC / Placebo OS Private Yes CRITICALLY LOW
Liu 2018 [33] China Up to March 15, 2017 Cochrane Central Register of Controlled Trials, Clinicaltrials.gov, EMBASE, EU Clinical Trials Register, Japan Pharmaceutical Information Center, PubMed. 8 4 Gastric and GEJ cancer Biological or targeted therapy Placebo OS, PFS, Toxicity Public / Private None LOW
Zhao 2018 [34] China Between 2002 and 2017 Cochrane Library, EMBASE, PubMed. 16 6 Esophageal, gastric and GEJ Biological or targeted therapy Placebo OS, PFS, Toxicity Public None CRITICALLY LOW
Chen 2019 [35] China Up to September 2018 PubMed 9 2 Gastric and GEJ cancer Immunotherapy BSC / Placebo OS, PFS, Toxicity Public None CRITICALLY LOW
van Kleef 2019 [36] Netherlands Up to April 2018 Cochrane Central Register of Controlled Trials, EMBASE, MEDLINE. 43 8 Esophageal, gastric and GEJ CT, Biological, or targeted therapy BSC / Placebo QoL Public Yes CRITICALLY LOW
Wallis 2019 [37] Canada Up to October 2, 2018 EMBASE, MEDLINE, PubMed, Scopus. 23 1 Gastric and GEJ cancer Immunotherapy Placebo OS Private Yes CRITICALLY LOW
  1. GEJ gastroesophageal junction, P patients, I intervention, C comparator, O outcomes, CT chemotherapy, BSC best supportive care, OS overall survival, PFS progression-free survival, QoL quality of life, NR not reported